drug

Lorazepam

MeSH D008140
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by GlaxoSmithKline
3 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

3
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567Phase 3Terminated
Effects of Pentazocine Versus Lorazepam on Manic Symptoms
NCT00431184Phase 2Completed
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
NCT00364429Phase 1Terminated

KOLs & investigators

2
Helge Frieling, Prof., MDKOL score 5
Beth L Murphy, MD/PhD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
GlaxoSmithKline
company
trial
Pharmacovigilance in Gerontopsychiatric Patients
PHASE3
trial
Effects of Pentazocine Versus Lorazepam on Manic Symptoms
PHASE2
trial
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
PHASE1
trial
indication
Schizophrenia
indication
Depression
indication
Psychosomatic Disorders
indication
Manic Disorder
indication
KOL
Helge Frieling, Prof., MD
KOL score 5
person
Beth L Murphy, MD/PhD
KOL score —
person